PureTech Health (PRTC) Competitors $16.50 -0.57 (-3.34%) Closing price 04:00 PM EasternExtended Trading$16.48 -0.02 (-0.09%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTC vs. DYN, APGE, TWST, BEAM, CDTX, IMCR, BHVN, WVE, AUPH, and TVTXShould you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Immunocore (IMCR), Biohaven (BHVN), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. PureTech Health vs. Its Competitors Dyne Therapeutics Apogee Therapeutics Twist Bioscience Beam Therapeutics Cidara Therapeutics Immunocore Biohaven WAVE Life Sciences Aurinia Pharmaceuticals Travere Therapeutics PureTech Health (NASDAQ:PRTC) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Is PRTC or DYN more profitable? PureTech Health's return on equity of 0.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PureTech HealthN/A N/A N/A Dyne Therapeutics N/A -64.12%-56.75% Which has preferable earnings and valuation, PRTC or DYN? PureTech Health has higher revenue and earnings than Dyne Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPureTech Health$6.17M64.58$27.78MN/AN/ADyne TherapeuticsN/AN/A-$317.42M-$3.86-3.50 Does the media refer more to PRTC or DYN? In the previous week, Dyne Therapeutics had 8 more articles in the media than PureTech Health. MarketBeat recorded 12 mentions for Dyne Therapeutics and 4 mentions for PureTech Health. Dyne Therapeutics' average media sentiment score of 1.40 beat PureTech Health's score of 0.47 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in PRTC or DYN? 0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, PRTC or DYN? PureTech Health has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Do analysts rate PRTC or DYN? PureTech Health currently has a consensus target price of $45.00, suggesting a potential upside of 172.73%. Dyne Therapeutics has a consensus target price of $34.07, suggesting a potential upside of 152.35%. Given PureTech Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe PureTech Health is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06 SummaryPureTech Health beats Dyne Therapeutics on 7 of the 13 factors compared between the two stocks. Get PureTech Health News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTC vs. The Competition Export to ExcelMetricPureTech HealthMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$411.93M$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E RatioN/A20.8682.5826.38Price / Sales64.58396.75535.42110.55Price / Cash7.1643.5325.7028.92Price / Book0.978.1011.196.58Net Income$27.78M-$53.35M$3.28B$265.84M7 Day Performance-13.59%-0.14%0.15%-0.07%1 Month Performance-13.57%9.18%8.34%5.83%1 Year Performance-28.26%7.53%54.21%17.88% PureTech Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTCPureTech Health2.3821 of 5 stars$16.50-3.3%$45.00+172.7%-25.8%$411.93M$6.17M0.00100Short Interest ↑DYNDyne Therapeutics3.7476 of 5 stars$13.00+3.3%$34.07+162.1%-70.7%$1.79BN/A-3.37100News CoveragePositive NewsAPGEApogee Therapeutics3.202 of 5 stars$36.94-3.5%$99.00+168.0%-28.9%$1.76BN/A-8.9491News CoveragePositive NewsTWSTTwist Bioscience3.8078 of 5 stars$27.39-4.2%$49.40+80.4%-37.6%$1.73B$312.97M-18.89990Positive NewsBEAMBeam Therapeutics2.309 of 5 stars$16.44-1.2%$48.45+194.7%-38.7%$1.68B$60.27M-3.65510News CoveragePositive NewsCDTXCidara Therapeutics3.7352 of 5 stars$64.13-3.4%$64.14+0.0%+450.0%$1.68B$1.27M-5.7690News CoveragePositive NewsIMCRImmunocore1.3812 of 5 stars$32.59-1.0%$56.89+74.6%-10.2%$1.66B$310.20M-81.48320News CoveragePositive NewsBHVNBiohaven3.7863 of 5 stars$14.96-4.2%$54.23+262.5%-61.0%$1.65BN/A-1.95239Trending NewsWVEWAVE Life Sciences4.6633 of 5 stars$9.94-2.1%$20.27+103.9%+67.2%$1.62B$108.30M-11.04240AUPHAurinia Pharmaceuticals2.7869 of 5 stars$12.14-1.1%$12.00-1.2%+76.1%$1.62B$235.13M28.23300News CoveragePositive NewsTVTXTravere Therapeutics1.9431 of 5 stars$17.23-3.9%$32.21+87.0%+84.8%$1.60B$333.87M-8.45460News CoverageAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies DYN Alternatives APGE Alternatives TWST Alternatives BEAM Alternatives CDTX Alternatives IMCR Alternatives BHVN Alternatives WVE Alternatives AUPH Alternatives TVTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTC) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share PureTech Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
